<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00354419</url>
  </required_header>
  <id_info>
    <org_study_id>2030.00</org_study_id>
    <secondary_id>NCI-2010-00191</secondary_id>
    <nct_id>NCT00354419</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant</brief_title>
  <official_title>A Dose Finding Study of Total Body Irradiation for Conditioning Patients With Severe Aplastic Anemia Transplanted With Umbilical Cord Blood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood
      stem cell transplant helps stop the growth of abnormal cells. It also helps stop the
      patient's immune system from rejecting the donor's stem cells. When the healthy stem cells
      from a donor are infused into the patient they may help the patient's bone marrow make stem
      cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells
      from a donor can make an immune response against the body's normal cells. Giving cyclosporine
      and mycophenolate mofetil before and after transplant may stop this from happening.

      PURPOSE: This phase I trial is studying the side effects and best dose of total-body
      irradiation when given together with cyclophosphamide and antithymocyte globulin in treating
      patients with severe aplastic anemia undergoing umbilical cord blood transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      I. The objective of this study is to determine the lowest dose of total body irradiation
      combined with cyclophosphamide and antithymocyte globulin that will achieve sustained
      engraftment in patients with severe aplastic anemia transplanted with unrelated umbilical
      cord blood.

      OUTLINE: This is a dose-escalation study of total-body irradiation (TBI).

      MYELOABLATIVE CONDITIONING REGIMEN: Patients receive cyclophosphamide IV on days -7 to -4, -6
      to -3, or -5 to -2 and antithymocyte globulin IV on days -6 to -4, -5 to -3, or -4 to -2.

      TBI: Patients undergo TBI twice daily on days -3, -2, and/or -1.

      UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT): Patients undergo UCBT on day 0. Patients receive
      filgrastim (G-CSF) IV or subcutaneously beginning on day 1 and continuing until blood counts
      recover.

      GRAFT-VS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive cyclosporine IV or orally (twice
      daily for patients &gt;= 6 years of age or 3 times daily for patients &lt; 6 years of age) on days
      -1 to +180 and mycophenolate mofetil IV or orally (twice daily for patients &gt;= 50 kg or 3
      times daily for patients &lt; 50 kg) beginning 4 hours after UCBT and continuing until
      approximately day +0.

      After completion of study therapy, patients are followed periodically.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual
  </why_stopped>
  <start_date>February 2006</start_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>Undergo radiotherapy</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
    <other_name>Enduxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>lymphocyte immune globulin</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>ciclosporin</other_name>
    <other_name>cyclosporin</other_name>
    <other_name>cyclosporin A</other_name>
    <other_name>CYSP</other_name>
    <other_name>Sandimmune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
    <description>Undergo transplantation</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>cord blood transplantation</other_name>
    <other_name>transplantation, umbilical cord blood</other_name>
    <other_name>UCB transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow aspiration</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given IV or SC</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>granulocyte colony-stimulating factor</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Life-threatening marrow failure of nonmalignant etiology meeting two of the three
             following criteria: granulocytes &lt; 500/mm^3; a corrected reticulocyte count &lt; 1%;
             platelet count &lt; 20,000/mm^3

          -  Failure to respond to the best available immunosuppressive treatment protocol by 75
             days after initiation of therapy

          -  Lack of an HLA-identical family member or closely matched (9 or 10 of 10 HLA-locus
             match) unrelated marrow donor

          -  DONOR: Unrelated UCB unit matched for at least 4 of 6 loci

          -  DONOR: Related UCB unit matched for at least 3 of 6 lock

          -  Selection of the UCB unit(s) will be based upon matching or mismatching at HLA-A, B
             antigen level and DRB1 allele level typing; while HLA-C antigen/allele and HLA-DQB1
             antigen/allele level typing are not considered in the matching criteria, if available
             each may be used to optimize unit selection

          -  Multiple UCB units are allowed to provide sufficient cell dose; when multiple units
             are selected, the following rules apply: a) the UCB unit with the least HLA disparity
             will be selected first (i.e., selection priority is 6/6 match &gt; 5/6 match &gt; 4/6
             match), additional UCB units may be selected to increase cell dose; b) UCB units must
             be matched to each other for at least 4 of 6 loci; c) each unit must contain at least
             1.5 x 10^7 Total Nucleated Cells per kg recipient weight; d) the total cell dose of
             the combined units must be at least 3.0 x 10^7 Total Nucleated Cells per kg recipient
             weight

        Exclusion Criteria:

          -  Severe disease other than aplastic anemia that would severely limit the probability of
             survival during the graft procedure; patients who present with active fungal
             infections must be treated to resolve this problem before beginning the conditioning
             regimen

          -  HIV seropositive patients

          -  Patients who have developed clonal cytogenetic abnormalities or a myelodysplastic
             syndrome (these patients will be considered in separate protocols for myelodysplastic
             syndrome, etc.)

          -  Patients with paroxysmal nocturnal hemoglobinuria or Fanconi anemia

          -  Patients &gt; 40 years of age

          -  Related or unrelated cord blood units with &lt; 1.5 x 10^7 Total Nucleated Cells per kg
             recipient weight

          -  Related or unrelated cord blood units without full testing and negative results for
             hepatitis A, B, C, HIV, HTLV-1, CMV viruses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Woolfrey</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2006</study_first_submitted>
  <study_first_submitted_qc>July 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2006</study_first_posted>
  <last_update_submitted>January 3, 2011</last_update_submitted>
  <last_update_submitted_qc>January 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Woolfrey, Ann</name_title>
    <organization>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

